Evidence map›Paper›PMID 39854310›Full record

ArticlePloS one2025

Low agreement and frequent invalid controls in two SARS-CoV-2 T-cell assays in people with compromised immune function.

Annette Audigé, Alain Amstutz, Macé M Schuurmans, Patrizia Amico, Dominique L Braun, Marcel P Stoeckle, Barbara Hasse, René Hage, Dominik Damm, Michael Tamm and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Annette AudigéInstitute of Medical Virology, University of Zurich, Zurich, Switzerland.
Alain AmstutzDivision of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
Macé M SchuurmansDivision of Pulmonology, University Hospital Zurich, Zurich, Switzerland.
Patrizia AmicoClinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland.
Dominique L BraunInstitute of Medical Virology, University of Zurich, Zurich, Switzerland.
Marcel P StoeckleDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel, Basel, Switzerland.
Barbara HasseDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
René HageDivision of Pulmonology, University Hospital Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0002-1994-7443
Dominik DammDivision of Pulmonology, University Hospital Zurich, Zurich, Switzerland.
Michael TammClinic of Respiratory Medicine and Pulmonary Cell Research, University Hospital Basel, Basel, Switzerland.
Nicolas J MuellerDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0002-1059-3191
Huldrych F GünthardInstitute of Medical Virology, University of Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0002-1142-6723
Michael T KollerClinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland.
Christof M SchönenbergerDivision of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
Alexandra GriessbachDivision of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
Niklaus D LabhardtDivision of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
Roger D KouyosInstitute of Medical Virology, University of Zurich, Zurich, Switzerland.
Alexandra TrkolaInstitute of Medical Virology, University of Zurich, Zurich, Switzerland.
Michael HuberInstitute of Medical Virology, University of Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0002-0384-0000
Katharina KusejkoInstitute of Medical Virology, University of Zurich, Zurich, Switzerland.
Heiner C BucherDivision of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
Irene A AbelaInstitute of Medical Virology, University of Zurich, Zurich, Switzerland.
Matthias BrielDivision of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.ORCID https://orcid.org/0000-0002-2070-5230
Frédérique ChammartinDivision of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
Benjamin SpeichDivision of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.ORCID https://orcid.org/0000-0002-3301-8085
Swiss HIV Cohort Study, and the Swiss Transplant Cohort Study

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T-cell response plays an important role in SARS-CoV-2 immunogenicity. For people living with HIV (PWH) and solid organ transplant (SOT) recipients there is limited evidence on the reliability of commercially available T-cell tests. We assessed 173 blood samples from 81 participants (62 samples from 35 PWH; 111 samples from 46 SOT recipients [lung and kidney]) with two commercial SARS-CoV-2 Interferon-γ (IFN-γ) release assays (IGRA; SARS-CoV-2 IGRA by Euroimmun, and IGRA SARS-CoV-2 by Roche). The reliability between the tests was judged as low (Cohen's kappa [κ] = 0.20; overall percent agreement [OPA] = 66%). A high proportion of tests were invalid (22% Euroimmun; 8% Roche). When excluding these invalid tests, the agreement was higher (κ  =  0.43; OPA = 90%). The low reliability between the two T-cell tests indicates that results should be interpreted with caution in SOT recipients and PWH and that SARS-CoV-2 T-cell tests need to be optimized and further validated for use in vulnerable patient populations.

Indexed as

COVID-19Immunocompromised HostInterferon-gamma Release TestsSARS-CoV-2T-LymphocytesAdultAgedFemaleHIV InfectionsHumansInterferon-gammaMaleMiddle AgedReproducibility of ResultsInterferon-gamma

Identifiers

PMID39854310
PMCPMC11761106

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.